April 17th 2024
Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
COMING SOON: Around the Practice: ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer
June 28th 2023Tanios S. Bekaii-Saab, MD, provides a look at an upcoming Cancer Network Around the Practice program in which a panel of experts will present the case of a patient with colorectal cancer, review updates from clinical trials, and provide insights on the role of ctDNA in treatment decision-making.
FDA Approves FoundationOne LiquidCDx for Encorafenib Combo in mCRC
June 12th 2023The FDA’s approval of the FoundationOne Liquid CDx as a companion diagnostic may improve access to treatment with encorafenib plus cetuximab for patients with metastatic colorectal cancer harboring a BRAF V600E alteration.
Preoperative FOLFOX Appears Noninferior Vs CRT in Rectal Cancer
June 4th 2023“We think that we can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates [and] keep patients disease free, with less long-term toxicity and effects,” lead author Deb Schrag, MD, FASCO, MPH, said.
Tucatinib/Trastuzumab Yields Durable Responses in HER2+ Metastatic CRC
June 2nd 2023Tucatinib plus trastuzumab represents a valuable, novel option for HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer that is chemotherapy refractory, according to the authors of the phase 2 MOUNTAINEER trial.
Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression
A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.